- Home
- ODD vs CELC Comparison
ODD vs CELC Comparison
Compare ODD & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | CELC |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 815.1M | 3.1B |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ODD | CELC |
|---|---|---|
| Price | $12.22 | $118.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $44.60 | ★ $100.13 |
| AVG Volume (30 Days) | ★ 3.5M | 521.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.55 | N/A |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.80 | $7.58 |
| 52 Week High | $79.18 | $120.32 |
Technical Indicators
Market Signals| Indicator | ODD | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 22.74 | 65.85 |
| Support Level | $10.80 | $97.75 |
| Resistance Level | $45.73 | $120.32 |
| Average True Range (ATR) | 1.68 | 5.05 |
| MACD | -0.50 | 1.02 |
| Stochastic Oscillator | 6.48 | 93.07 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.